Molecular Formula | C23H39NO4 |
Molar Mass | 393.56 |
Melting Point | 181-183°C |
Solubility | DMSO: ≥5mg/mL |
Appearance | powder |
Color | white to tan |
Storage Condition | 2-8°C |
In vitro study | At 24, 48 and 72 h of treatment with 0.01 and 1 μM of Perhexiline , NDM29 ncRNA expression level in SH-SY5Y cells is progressively increased, reaching a peak after 48 hours of treatment. Perhexiline treatment increases the susceptibility of NB cells to antiblastic treatments. Co-administration of Perhexiline maleate potentiates the efficacy of cisplatin to reduce the in vitro clonogenic potential of NB cells. |
In vivo study | The co-administration of Perhexiline and cisplatin yields a clear enhancement of antitumor effects, resulting in a significantly improved progression-free survival as compared with mice treated with DMSO. Perhexiline favors NB cell transition to differentiated phenotype. |
WGK Germany | 2 |
RTECS | TM7068000 |
Toxicity | LD50 in rats, mice (g/kg): >7, 4.37 orally (Causa, Perri) |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.541 ml | 12.705 ml | 25.409 ml |
5 mM | 0.508 ml | 2.541 ml | 5.082 ml |
10 mM | 0.254 ml | 1.27 ml | 2.541 ml |
5 mM | 0.051 ml | 0.254 ml | 0.508 ml |